CMP ICD-10-CM Codes | 2023
The CMP ICD-10-CM Codes provide a comprehensive and standardized system for medical diagnosis coding. Improve accuracy and efficiency in healthcare.
What ICD-10 Codes are Used for CMP
ICD-10-CM codes are crucial in accurately documenting and coding medical conditions, including Chronic Myeloproliferative Neoplasms (CMP). Here are some commonly used ICD-10 codes for CMP:
D45.0 - Polycythemia Vera (PV):
This code represents the presence of PV, a disorder involving the overproduction of red blood cells. Clinical manifestations may include increased hematocrit levels, splenomegaly (enlarged spleen), thrombosis, and pruritus (itching).
D47.3 - Essential Thrombocythemia (ET):
The excessive production of platelets in the bone marrow characterizes ET. Patients with ET may experience thrombosis, bleeding, headache, and an enlarged spleen.
D47.4 - Osteomyelofibrosis (Primary Myelofibrosis):
Osteomyelofibrosis, also known as primary myelofibrosis, is a disorder where the bone marrow is replaced by fibrous tissue. Symptoms may include anemia, splenomegaly, bone pain, fatigue, and increased infection susceptibility.
D47.1 - Chronic Myelofibrosis:
Chronic myelofibrosis is characterized by the progressive replacement of bone marrow by fibrous tissue. Common clinical features include anemia, splenomegaly, fatigue, weight loss, and abdominal discomfort.
D46.4 - Refractory Anemia with Excess Blasts:
This code indicates the presence of refractory anemia with excess blasts, a subtype of myelodysplastic syndrome. Patients may exhibit symptoms of anemia, thrombocytopenia (low platelet count), and abnormal blast cells in the bone marrow.
D46.9 - Myelodysplastic Syndrome, Unspecified:
This code is used when a specific subtype of myelodysplastic syndrome is not specified. A myelodysplastic syndrome is a group of disorders characterized by abnormal blood cell production in the bone marrow.
D46.0 - Refractory Anemia:
Refractory anemia is a subtype of myelodysplastic syndrome characterized by persistent low red blood cell production. Clinical features may include fatigue, weakness, pale skin, and an increased risk of infections.
D47.2 - Monoclonal Gammopathy:
Monoclonal gammopathy refers to the presence of an abnormal protein (M protein) in the blood. This code is used when monoclonal gammopathy is associated with CMP.
D47.9 - Neoplasms of Uncertain Behavior of Lymphoid, Hematopoietic, and Related Tissue:
This code is used when the specific CMP subtype is not specified or further evaluation is required for a definitive diagnosis. It represents neoplasms of uncertain behavior in the lymphoid, hematopoietic, or related tissue.
C92.1 - Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission:
This code is not specific to CMP but represents chronic myeloid leukemia (CML) in remission. It is included here as CML can sometimes be associated with CMP.
Which CMP ICD codes are Billable:
D45.0 - Polycythemia Vera (PV):
PV is a billable code as it represents a specific condition characterized by the overproduction of red blood cells and has distinct clinical manifestations.
D47.3 - Essential Thrombocythemia (ET):
ET is a billable code as it refers to the excessive production of platelets and has identifiable clinical features that require medical attention.
D47.4 - Osteomyelofibrosis (Primary Myelofibrosis):
Osteomyelofibrosis is a billable code as it signifies the replacement of bone marrow by fibrous tissue and presents associated symptoms that necessitate medical coding.
D47.1 - Chronic Myelofibrosis:
Chronic Myelofibrosis is a billable code as it represents the progressive replacement of bone marrow and is associated with specific clinical manifestations.
D46.4 - Refractory Anemia with Excess Blasts:
Refractory anemia with excess blasts is a billable code. It describes a distinct subtype of a myelodysplastic syndrome characterized by abnormal blast cells and requires appropriate medical coding for accurate billing.
D46.9 - Myelodysplastic Syndrome, Unspecified:
Myelodysplastic Syndrome, when not specified, is a billable code as it encompasses a range of disorders involving abnormal blood cell production and requires medical attention and appropriate coding.
D46.0 - Refractory Anemia:
Refractory anemia is a billable code as it signifies a specific subtype of a myelodysplastic syndrome characterized by persistent low red blood cell production. It requires accurate medical coding for billing purposes.
D47.2 - Monoclonal Gammopathy:
Monoclonal gammopathy is not a billable code as it does not specifically represent CMP. It may require additional codes or documentation to link it to CMP for billing purposes.
D47.9 - Neoplasms of Uncertain Behavior of Lymphoid, Hematopoietic, and Related Tissue:
Neoplasms of uncertain behavior are not billable codes as they indicate an uncertain diagnosis. Further evaluation and specific diagnosis are required for appropriate billing.
C92.1 - Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission:
While this code is not specific to CMP, it is billable as it represents chronic myeloid leukemia in remission and can be associated with CMP in some cases.
Clinical Information
CMP (Chronic Myeloproliferative Neoplasms) are a group of blood disorders characterized by the overproduction of blood cells. They result from genetic mutations leading to abnormal cell growth. Here are key clinical points:
- Chronic Myeloproliferative Neoplasms (CMP) are a group of blood disorders characterized by abnormal overproduction of blood cells in the bone marrow, including subtypes such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), and chronic myeloid leukemia (CML).
- PV is characterized by the excessive production of red blood cells, leading to increased blood viscosity, potential complications like blood clots, and symptoms such as headache, fatigue, and itching.
- ET involves an abnormal increase in platelet production, leading to an elevated risk of bleeding, blood clot formation, and symptoms like easy bruising, nosebleeds, and headache.
- MF is a progressive form of CMP where normal bone marrow is replaced by fibrous tissue, causing anemia, enlarged spleen, fatigue, bone pain, and increased susceptibility to infections.
- CML is caused by the Philadelphia chromosome, resulting in uncontrolled growth of myeloid cells, leading to anemia, fatigue, night sweats, weight loss, abdominal pain, and enlarged spleen.
- Diagnosis of CMP involves blood tests, bone marrow biopsy, and genetic testing to identify specific mutations. Treatment options include targeted therapies, chemotherapy, stem cell transplantation, and supportive care to manage symptoms and complications.
Synonyms Include:
- Chronic myeloproliferative neoplasms
- Myeloproliferative disorders
- Myeloproliferative neoplasms
- Myeloproliferative diseases
- Chronic myeloproliferative disorders
- Myeloproliferative syndrome
- Chronic myeloid disorders
- Chronic myeloid neoplasms
- Myeloproliferative malignancies
- Chronic myeloid proliferative diseases
Commonly asked questions
Risk factors for CMP are not well-defined, but certain genetic mutations and family history of CMP may increase the risk of developing the condition. While most cases of CMP are not inherited, specific genetic mutations associated with CMP can be passed down within families, increasing the risk of developing the condition.
Some CMP subtypes, such as PV and ET, have a relatively stable course. In contrast, others like MF and advanced-stage CML can progress to acute leukemia or have more aggressive disease manifestations.
Long-term complications of CMP can include blood clotting disorders, bleeding complications, transformation to acute leukemia, progressive bone marrow fibrosis, and the potential need for stem cell transplantation in some cases.